Alcoholism Clinical Trial
Official title:
Randomized Controlled Trial of a Multi-pronged Intervention to Address Prevention of Violence in Zambia
NCT number | NCT02790827 |
Other study ID # | IRB00006534 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | May 2016 |
Est. completion date | January 2019 |
Verified date | March 2019 |
Source | Johns Hopkins Bloomberg School of Public Health |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study evaluates the effectiveness of a multi-pronged intervention in reducing and preventing violence against women and children compared to a treatment as usual control group among families living in Lusaka, Zambia.
Status | Completed |
Enrollment | 626 |
Est. completion date | January 2019 |
Est. primary completion date | January 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 8 Years and older |
Eligibility |
Inclusion Criteria: 1. Families living in the study compounds in Lusaka (i.e., not staying temporarily) 2. Speaking one of the three study languages: English, Bemba, or Nyanja 3. Having at least one male adult and one female adult 18 years of age or older and in a relationship (married or dating) and one child between the ages of 8 to 17 identified by the mother as the most affected by the violence (if multiple children in the home). Child participation is optional. 4. The man and woman must both provide consent. If the female agree to have the child participate and the child wants to participate, then parental permission and child assent will be required. 5. The adult female must indicate during the inclusion screening at least a moderate amount of violence within the family as measured by scoring a 38 or more on the Severity of Violence Against Women Scale (SVAWS). 6. The male in the family must indicate that he drinks alcohol at hazardous levels or the female must report that the male drinks alcohol at hazardous levels as evidenced by scoring an 8 or higher on the Alcohol Use Disorders Identification Test (AUDIT). Exclusion Criteria: 1. Any of the family members is currently on an unstable psychiatric drug regimen (i.e., regimen altered in last 2 months) 2. Any of the family members has had a suicide attempt or suicidal ideation with intent or plan, or self-harm in the past month. 3. Any of the family members has been diagnosed with a current psychotic disorder (identified by the University Teaching Hospital Psychiatric Unit). 4. Any of the family members has a serious developmental disorder (e.g., mental retardation, autism) that would preclude participation in cognitive-behavioral oriented skills intervention |
Country | Name | City | State |
---|---|---|---|
Zambia | Serenity Harm Reduction Programme Zambia (SHARPZ) | Lusaka |
Lead Sponsor | Collaborator |
---|---|
Johns Hopkins Bloomberg School of Public Health | SHARPZ (Serenity Harm Reduction Programme Zambia) |
Zambia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in violence against women as measured by Severity of Violence Against Women Scale (SVAWS) | Baseline, 4-5 months post-baseline, 12 months post-baseline, 24 months post-baseline | ||
Secondary | Change in alcohol abuse as measured by the Alcohol Use Disorders Identification Test (AUDIT) | Baseline, 4-5 months post-baseline, 12 months post-baseline, 24 months post-baseline | ||
Secondary | Change in child abuse as measured by the Youth Victimization Scale | Baseline, 4-5 months post-baseline, 12 months post-baseline, 24 months post-baseline | ||
Secondary | Change in depression symptoms as measured by the Center for Epidemiological Studies Depression Scale (CES-D) | Baseline, 4-5 months post-baseline, 12 months post-baseline, 24 months post-baseline | ||
Secondary | Change in PTSD symptoms (adult) as measured by the Harvard Trauma Questionnaire (HTQ) | Baseline, 4-5 months post-baseline, 12 months post-baseline, 24 months post-baseline | ||
Secondary | Change in belief about gender norms as measured by the Gender Equitable Mens Scale (GEMS) | Baseline, 4-5 months post-baseline, 12 months post-baseline, 24 months post-baseline | ||
Secondary | Change in child internalizing and externalizing symptoms as measured by the Youth Self Report (YSR) | Baseline, 4-5 months post-baseline, 12 months post-baseline, 24 months post-baseline | ||
Secondary | Change in substance use as measured by the Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) | Baseline, 4-5 months post-baseline, 12 months post-baseline, 24 months post-baseline | ||
Secondary | Change in child aggression as measured by the Child Aggression Scale | Baseline, 4-5 months post-baseline, 12 months post-baseline, 24 months post-baseline | ||
Secondary | Change in PTSD symptoms (child) as measured by the Child PTSD Symptom Scale (CPSS) | Baseline, 4-5 months post-baseline, 12 months post-baseline, 24 months post-baseline | ||
Secondary | Change in chronic stress as measured by hair cortisol | Baseline, 4-5 months post-baseline, 12 months post-baseline, 24 months post-baseline | ||
Secondary | Change in psychological violence as measured by Index of Psychological Abuse | Baseline, 4-5 months post-baseline, 12 months post-baseline, 24 months post-baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05054738 -
CRP and S&A for Inpatient Veterans
|
N/A | |
Completed |
NCT02233738 -
Group Motivational Interviewing (GMI) For Homeless Veterans In VA Services
|
N/A | |
Completed |
NCT05877807 -
Effect of Baclofen to Prevent Post-Traumatic Stress Disorder
|
||
Completed |
NCT00000437 -
Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone)
|
Phase 4 | |
Completed |
NCT00536146 -
The Stress-Hormone System in Alcohol-Dependent Subjects
|
N/A | |
Terminated |
NCT00890149 -
Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults
|
Phase 2 | |
Completed |
NCT02179749 -
Mifepristone Treatment of Alcohol Use Disorder
|
Phase 2 | |
Completed |
NCT02939352 -
The Effects of Theta Burst Stimulation on the Brain Response to Drug and Alcohol Cues
|
Early Phase 1 | |
Completed |
NCT01553136 -
Varenicline Treatment of Alcohol Dependence in Smokers
|
Phase 2 | |
Terminated |
NCT01408641 -
Topiramate for Alcohol Use in Posttraumatic Stress Disorder
|
N/A | |
Completed |
NCT01389297 -
Overcoming Addictions: A Randomized Clinical Trial of a Web Application Based on SMART Recovery
|
N/A | |
Completed |
NCT01760785 -
Valproate for Mood Swings and Alcohol Use Following Head Injury
|
N/A | |
Completed |
NCT01113164 -
Matching Genotypes and Serotonergic Medications for Alcoholism
|
Phase 1 | |
Completed |
NCT00768508 -
Combined Pharmacotherapies for Alcoholism
|
Phase 3 | |
Terminated |
NCT02842528 -
Cognitive Vulnerability Factors in Alcohol-dependence
|
N/A | |
Completed |
NCT00127231 -
Brief Therapy Intervention for Heavy/Hazardous Drinking in HIV-Positive Women
|
N/A | |
Completed |
NCT00367575 -
An Internet-based Intervention for Problem Drinking
|
N/A | |
Completed |
NCT00583440 -
12-step Facilitation for the Dually Diagnosed
|
Phase 1/Phase 2 | |
Completed |
NCT00167687 -
Prazosin Alcohol Dependence IVR Study
|
Phase 4 | |
Completed |
NCT00223639 -
New Medications to Treat Alcohol Dependence
|
Phase 2 |